BUSINESS

United States drugmaker adopts NVIDIA Vera Rubin supercomputer

▪

Read, Watch or Listen

On July 20, 2026, Bristol Myers Squibb (BMS), a global biopharmaceutical company based in the United States, announced an expanded partnership with NVIDIA to significantly scale its artificial intelligence capabilities for drug discovery. BMS will deploy an NVIDIA DGX SuperPOD powered by next-generation DGX Vera Rubin NVL72 systems, described as the most powerful and energy-efficient single-owned NVIDIA compute infrastructure in the life sciences sector. The Vera Rubin architecture, which succeeds NVIDIA’s Blackwell and Hopper platforms, is designed to deliver up to a tenfold increase in performance per megawatt, enabling BMS to run large, complex AI workloads while constraining energy use and operational costs.

Prepared by Christopher Adams and reviewed by editorial team.

Timeline of Events

2023 BMS completes three-year NVIDIA collaboration
Early 2026 NVIDIA unveils Vera Rubin architecture
Early 2026 BMS evaluates next-generation AI hardware
July 20, 2026 BMS announces expanded NVIDIA partnership
July 20, 2026 Company confirms DGX SuperPOD deployment
July 20, 2026 Vera Rubin NVL72 systems selected
Following months BMS transitions core discovery workflows
Future years AI supports large-scale foundation model training

Why This Matters to You

This partnership could speed up drug discovery, potentially leading to faster treatments for various diseases. If you or a loved one are waiting for medical breakthroughs, this could be promising news. Keep an eye on BMS's announcements for updates.

The Bottom Line

BMS's adoption of NVIDIA's supercomputer is a big step in AI-powered drug discovery. It's a sign of how technology is transforming healthcare. Worth forwarding if you know someone interested in the intersection of tech and health.